Inspire Medical Systems, Inc. (NYSE:INSP) Shares Sold by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC lowered its position in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 6.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,836 shares of the company’s stock after selling 126 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Inspire Medical Systems were worth $246,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Van ECK Associates Corp increased its stake in Inspire Medical Systems by 7.5% in the second quarter. Van ECK Associates Corp now owns 1,029 shares of the company’s stock valued at $138,000 after purchasing an additional 72 shares during the last quarter. Amalgamated Bank lifted its holdings in shares of Inspire Medical Systems by 4.1% during the 2nd quarter. Amalgamated Bank now owns 2,005 shares of the company’s stock worth $268,000 after acquiring an additional 79 shares during the period. Bessemer Group Inc. boosted its position in shares of Inspire Medical Systems by 1.2% in the first quarter. Bessemer Group Inc. now owns 8,475 shares of the company’s stock worth $1,820,000 after acquiring an additional 100 shares during the last quarter. Treasurer of the State of North Carolina grew its holdings in Inspire Medical Systems by 1.0% in the fourth quarter. Treasurer of the State of North Carolina now owns 12,750 shares of the company’s stock valued at $2,594,000 after purchasing an additional 120 shares during the period. Finally, Gilliland Jeter Wealth Management LLC increased its position in Inspire Medical Systems by 0.8% during the second quarter. Gilliland Jeter Wealth Management LLC now owns 15,508 shares of the company’s stock worth $2,075,000 after purchasing an additional 125 shares during the last quarter. 94.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Morgan Stanley dropped their price objective on Inspire Medical Systems from $250.00 to $210.00 and set an “overweight” rating for the company in a report on Monday, July 15th. Truist Financial decreased their target price on Inspire Medical Systems from $280.00 to $217.00 and set a “buy” rating for the company in a report on Tuesday, July 16th. Royal Bank of Canada restated an “outperform” rating and issued a $260.00 price target on shares of Inspire Medical Systems in a report on Wednesday, August 7th. Robert W. Baird decreased their price objective on shares of Inspire Medical Systems from $220.00 to $200.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Finally, Bank of America cut their target price on shares of Inspire Medical Systems from $225.00 to $185.00 and set a “neutral” rating on the stock in a research note on Monday, June 3rd. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, Inspire Medical Systems has an average rating of “Moderate Buy” and an average target price of $214.85.

Inspire Medical Systems Trading Down 2.2 %

Shares of NYSE INSP opened at $202.48 on Monday. Inspire Medical Systems, Inc. has a 12-month low of $123.00 and a 12-month high of $257.40. The company has a market cap of $6.02 billion, a PE ratio of -368.15 and a beta of 1.33. The stock has a 50 day simple moving average of $183.08 and a 200-day simple moving average of $182.41.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.46. Inspire Medical Systems had a return on equity of 1.03% and a net margin of 0.85%. The company had revenue of $195.89 million during the quarter, compared to analysts’ expectations of $189.08 million. During the same quarter in the prior year, the business posted ($0.41) earnings per share. The company’s revenue for the quarter was up 29.6% compared to the same quarter last year. Sell-side analysts forecast that Inspire Medical Systems, Inc. will post 0.75 earnings per share for the current fiscal year.

Insider Buying and Selling at Inspire Medical Systems

In related news, Director Shawn Mccormick sold 800 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $220.00, for a total transaction of $176,000.00. Following the transaction, the director now owns 23,140 shares in the company, valued at $5,090,800. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Inspire Medical Systems news, Director Shawn Mccormick sold 800 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $220.00, for a total transaction of $176,000.00. Following the completion of the transaction, the director now directly owns 23,140 shares of the company’s stock, valued at approximately $5,090,800. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Randy Ban sold 4,861 shares of the business’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $188.55, for a total value of $916,541.55. Following the completion of the sale, the insider now directly owns 3,056 shares in the company, valued at approximately $576,208.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,692 shares of company stock valued at $1,099,207. Company insiders own 4.10% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.